Impressed by survival data, FDA hastens review in expanded patient group
Tesaro’s PARP drug approved in wider ovarian cancer population
AI blood test achieves very high accuracy and specificity for detecting ovarian cancer.
EU regulators recommend PARP inhibitor Zejula
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
FDA approves Lynparza’s use in a wider group of women.
Circulating tumour cell test could help select drug therapy.
US biotech looks to bolster pipeline.
Tesara and Takeda among other companies to publish data.